Minerva Neurosciences (NERV) Tops Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Minerva Neurosciences Reports Fourth Quarter and Full Year 2014 Financial Results
March 26, 2015 4:01 PM EDT- MIN-101 Phase 2b trial for schizophrenia on track - - Phase 2a trial planned for MIN-202 in primary insomnia in mid-2015; Phase 1b in MDD patients also expected to begin in mid-2015 - - Company advancing CNS pipeline with MIN-117 and MIN-301 - - Management to host conference call today at 4:30 p.m. ET -
WALTHAM, Mass., March 26, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) diseases... More
Minerva Neurosciences Reports Fourth Quarter and Full Year 2014 Financial Results
March 26, 2015 4:01 PM EDT- MIN-101 Phase 2b trial for schizophrenia on track - - Phase 2a trial planned for MIN-202 in primary insomnia in mid-2015; Phase 1b in MDD patients also expected to begin in mid-2015 - - Company advancing CNS pipeline with MIN-117 and MIN-301 - - Management to host conference call today at 4:30 p.m. ET -
WALTHAM, Mass., March 26, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) diseases... More
